Kidney Cancer, Version 3.2015

Featured Updates to the NCCN Guidelines

Robert J. Motzer, MD; Eric Jonasch, MD; Neeraj Agarwal, MD; Clair Beard, MD; Sam Bhayani, MD; Graeme B. Bolger, MD; Sam S. Chang, MD; Toni K. Choueiri, MD; Brian A. Costello, MD, MS; Ithaar H. Derweesh, MD; Shilpa Gupta, MD; Thomas Olencki, DO; Robert J. Motzer, MD; Edward N. Rampersaud, MD; Bruce G. Redman, DO; Charles J. Ryan, MD; Joel Sheinfeld, MD; Brian Shuch, MD; Kanishka Sircar, MD; Brad Somer, MD; Richard B. Wilder, MD; Mary Dwyer, MS; and Rashmi Kumar, PhD

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma. (J Natl Compr Canc Netw 2015;13:151–159)

From 1Memorial Sloan Kettering Cancer Center; 2The University of Texas MD Anderson Cancer Center; 3Huntsman Cancer Institute at the University of Utah; 4Dana-Farber/Brigham and Women’s Cancer Center; 5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 6University of Alabama at Birmingham Comprehensive Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8Mayo Clinic Cancer Center; 9UC San Diego Moores Cancer Center; 10Moffitt Cancer Center; 11Stanford Cancer Institute; 12The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14University of Colorado Cancer Center; 15City of Hope Comprehensive Cancer Center; 16Roswell Park Cancer Institute; 17University of Washington/Seattle Cancer Care Alliance; 18Massachusetts General Hospital Cancer Center; 19The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 20Fox Chase Cancer Center; 21Duke Cancer Institute; 22University of Michigan Comprehensive Cancer Center; 23UCSF Helen Diller Family Comprehensive Cancer Center; 24Yale Cancer Center/Smilow Cancer Hospital; 25St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; and 26National Comprehensive Cancer Network.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes to the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guideline Panel discussion, including the literature reviewed.

These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

*Provided content development and/or authorship assistance.
NCCN: Continuing Education

Accreditation Statement
This activity is designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Disclosure of Relevant Financial Relationships

Editor:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE Authors:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

Individuals Who Provided Content Development and/or Authorship Assistance:
Robert J. Motzer, MD, Panel Chair, has disclosed the following relationships with commercial interests: consultant fees/honoraria from AVEO Oncology, Bayer HealthCare, Genentech, Inc., and Pfizer Inc.; and grant/research support from AVEO Oncology, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Eric Jonasch, MD, Panel Vice-Chair, has disclosed the following relationships with commercial interests: consultant fees/honoraria from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pfizer Inc.; and grant/research support from Exelixis Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships.

Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Kidney Cancer, Version 3.2015

Overview

Renal cell carcinoma (RCC) constitutes approximately 3.9% of new cancers, with a median age of 64 years at diagnosis. The American Cancer Society estimated that 63,920 Americans would be diagnosed with and 13,860 would die of RCC in the United States in 2014. The rate of RCC has increased by 1.6% per year for the past 10 years (2002–2011). Analysis of the SEER database, however, indicates that the 5-year survival rate for kidney cancer has increased over time for localized disease (from 88.4% during 1992–1995 to 91.8% during 2004–2010) and advanced disease (from 7.3% during 1992–1995 to 12.3% during 2004–2010). This improvement in survival may be attributed to the recent advances in treatment options for patients with RCC.

The NCCN Kidney Cancer Panel is a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncology...
Axitinib as First-Line Therapy for Patients With Predominantly Clear Cell RCC

Patients with predominantly clear cell RCC treated with axitinib, 5 mg orally twice daily in the second-line setting demonstrated greater objective response and longer median progression-free survival (PFS) compared with those treated with sorafenib, 400 mg orally twice daily. To determine whether this held true in the first-line setting, a randomized, open-label, phase III trial was performed in newly diagnosed patients randomized (2:1) to receive axitinib (5 mg, twice daily) or sorafenib (400 mg, twice daily).³ The median PFS in patients treated with axitinib was 10.1 months (95% CI, 7.2–12.1) versus 6.5 months with sorafenib (95% CI, 4.7–8.3), a difference that was not statistically significant.³ The adverse events more commonly seen with axitinib (≥10% difference) than with sorafenib included diarrhea, hypertension, weight loss, decreased appetite, dysphonia, hypothyroidism, and upper abdom-
inal pain, whereas those more commonly seen with sorafenib included palmar-plantar erythrodysesthesia, rash, alopecia, and erythema. Even though the difference in PFS between patients treated with axitinib versus sorafenib was not statistically significant, these results showed that axitinib had clinical activity and an acceptable toxicity profile in the first-line setting.

Another randomized multicenter phase II trial evaluated the efficacy and safety of axitinib dose escalation in patients with newly diagnosed metastatic RCC. In this study, all patients received axitinib, 5 mg twice daily for 4 weeks. They were then assigned (1:1) to undergo upward titration of axitinib or continuation of axitinib, 5 mg twice daily plus placebo titration. The axitinib dose was increased in the study arm to 7 mg orally twice per day, and if tolerated, was increased up to a maximum of 10 mg orally twice per day. More patients in the axitinib titration group experienced an objective response than those treated with axitinib, 5 mg orally twice daily (54% vs 34%), although PFS was not different between groups.

Based on the findings from the studies described, the NCCN Kidney Cancer Panel included axitinib as an option for the first-line treatment of patients with predominantly clear cell carcinoma (category 2A; see KID-3, page 153).

Pazopanib as Subsequent Therapy for Predominantly Clear Cell Carcinoma

The safety and effectiveness of pazopanib in patients who received first-line cytokines was evaluated in a phase III, open-label, international, multicenter study, which randomized patients to either pazopanib, 800 mg orally daily, or placebo. Of the 435 patients with advanced clear cell RCC, 202 had received prior cytokine therapy. The average PFS in cytokine pretreated patients was 7.4 months in pazopanib-treated patients versus 4.2 months in...
placebo-treated patients. Based on the results of this trial, the NCCN Kidney Cancer Panel included pazopanib as a category 1 option after cytokine therapy.

Until now, the use of pazopanib after progression on a first-line tyrosine kinase inhibitor was listed as a category 3 recommendation because of lack of data in this setting. Recently, a prospective phase II trial examined the activity and toxicity of second-line treatment with pazopanib (800 mg, orally daily) in 56 patients with advanced metastatic RCC. The patients enrolled in this trial had received first-line treatment with sunitinib (n=39) or bevacizumab (n=16). Responses were evaluated after 8 weeks of treatment using RECIST. The trial showed that 27% of patients (n=15) had an objective response to pazopanib and 49% (n=27) had stable disease. After a median follow-up of 16.7 months, the median PFS was 7.5 months (95% CI, 5.4–9.4 months). The PFS was similar whether previous treatment was with sunitinib or bevacizumab. The estimated overall survival rate at 24 months was 43%.

A retrospective analysis reported data on 93 patients with metastatic RCC treated with multiple lines of prior targeted therapies and who were subsequently treated with pazopanib. Among 85 evaluable patients, 15% (n=3) had a partial response and the observed median PFS was 6.5 months (95% CI, 4.5–9.7).

Based on these data, the use of pazopanib is now listed as a category 2A recommendation after tyrosine kinase failure in the updated NCCN Guidelines for Kidney Cancer (see KID-3, page 153).

Follow-up of Patients With Kidney Cancer
The updated NCCN Guidelines provide a framework for follow-up of patients undergoing surveillance of a small renal mass, those who underwent surgery or ablative therapy of a primary RCC, and those under-
going systemic therapy for advanced disease. These NCCN Guidelines incorporate a risk-stratified use of imaging that may target the patients most in need of intensive surveillance and/or imaging tests during follow-up.

The panel has reiterated in a footnote that no single follow-up plan is appropriate for everyone, and follow-up should be modified for the individual patient using clinical judgement. Because uniform consensus is lacking among the panel members regarding the most appropriate follow-up plan, these recommendations are listed as category 2B (see KID-B, 1–4 of 4; pages 154–157). Additionally, the NCCN Guidelines include follow-up for the first 5 years after nephrectomy, with follow-up evaluation to be extended beyond 5 years at the discretion of the physician. Results from a retrospective analysis indicate that in a subset of patients, relapses occur more than 5 years after surgery for their primary RCC. This report suggests that continued follow-up/surveillance after 5 years may be of potential value in some patients. Identification of subsets of patients with higher risk that require longer follow-up has not been defined, and further research is required to refine follow-up strategies for patients with RCC.

**Follow-up During Active Surveillance for Stage pT1a RCC**

For follow-up during active surveillance, the NCCN Guidelines recommend a history and physical examination, comprehensive metabolic panel, and other tests every 6 months for the first 2 years and then annually up to 5 years after diagnosis. To study the growth rate of the tumor, the panel recommends abdominal imaging (with CT or MRI) within 6 months from initiation of active surveillance, and subsequent imaging (with CT, MRI, or ultrasound) may be performed annually thereafter. All 3 modalities (ultrasound, CT, and MRI) have been found to
accurately predict pathologic tumor size in a retrospective analysis. Therefore, best clinical judgement should be used in choosing the imaging modality. For patients with biopsy-proven RCC, the recommendation is to assess annually for pulmonary metastases using chest imaging techniques (radiograph or CT). The panel recommends imaging of the pelvis; CT or MRI of the head or MRI of the spine in the presence of neurologic symptoms; or bone scan in cases of elevated alkaline phosphatase (ALP), bone pain, or abnormal radiologic findings.

**Follow-up After Ablative Therapy for Stage pT1a RCC**
Most follow-up tests recommended by the panel after ablative therapy are similar to those included during active surveillance. For imaging tests after ablative therapy, the panel recommends abdominal CT or MRI with or without intravenous contrast unless otherwise contraindicated at 3 and 6 months to assess treatment response, followed by annual abdominal CT or MRI scans for 5 years. The panel recommends annual chest radiograph or chest CT for 5 years to assess for pulmonary metastases in patients who have biopsy-proven low-risk RCC, nondiagnostic biopsies, or no prior biopsy to assess for liver metastases. The panel suggests repeat biopsy if radiographic evidence shows progressive increase in size of an ablated neoplasm with or without contrast enhancement, new nodularity in or around the treated zone, failure of the treated lesion to regress over time, or the presence of satellite or port site lesions.

**Follow-up After Nephrectomy for Stage I–III RCC**
For patients with stages pT1a and pT1b RCC after partial or radical nephrectomy, the panel recommends a history and physical examination, comprehensive metabolic panel, and other tests be performed every 6 months for 2 years, and then annually up to 5 years after nephrectomy. The panel recommends a baseline abdominal scan (CT, MRI, or ultrasound) for patients undergoing either partial or radical nephrectomy within 3 to 12 months after renal surgery. If the initial postoperative imaging shows negative results, abdominal imaging beyond 12 months for patients who have undergone radical nephrectomy may be performed at the discretion of the physician; for those who have undergone partial nephrectomy, abdominal scans (CT, MRI, or ultrasound) may be considered annually for 3 years based on individual risk factors.

Local recurrence rates for smaller tumors after partial nephrectomy are 1.4% to 2.0% versus 10.0% for larger tumors. The panel recommends yearly chest imaging (chest radiograph or CT) for 3 years, and as clinically indicated thereafter. Imaging of the pelvis, CT or MRI of the head or MRI of the spine, or bone scan is recommended as clinically indicated.

**Follow-up for Patients With Stage II–III RCC After Radical Nephrectomy**
Larger tumors have a substantially higher risk of both local and metastatic recurrence; therefore, an increase in frequency of examinations is recommended compared with patients with stages pT1a or pT1b. The panel recommends a history and physical examination every 3 to 6 months for 3 years, then annually up to 5 years after radical nephrectomy, and thereafter as clinically indicated. Comprehensive metabolic panel tests and other tests as indicated every 6 months for 2 years, then annually up to 5 years after radical nephrectomy, and thereafter as clinically indicated.

The panel recommends baseline chest imaging (with CT) and abdominal scans (CT or MRI) within 3 to 6 months after radical nephrectomy, with continued imaging (CT or radiograph of the chest; CT, MRI, or ultrasound of the abdomen) every 3 to 6 months for at least 3 years, and then annually thereafter for up to 5 years. Although the use of ultrasound imaging for follow-up is an option for low-risk patients, CT is the preferred modality for those with a high risk of recurrence. Disagreement exists among the panel members regarding the usefulness of ultrasound in patients with stage III disease; therefore, it is listed as a category 2B option specifically for patients with stage II disease. The panel has noted that imaging beyond 5 years may be performed as clinically indicated, and site-specific imaging performed as symptoms warrant. Other tests, such as imaging of the pelvis, CT or MRI of the head or MRI of the spine, or bone scan, are recommended as clinically indicated.

**Follow-up for Relapsed or Stage IV and Surgically Unresectable RCC**
Patients with relapsed or stage IV and unresectable disease often receive systemic therapy. For these patients, the panel recommends a history and physical examination every 6 to 16 weeks, or more frequently as clinically indicated, adjusting according to the type of systemic therapy the patient is receiving. The panel
Kidney Cancer, Version 3.2015

It recommends laboratory tests as per requirements for the therapeutic agent being used. For the chest, abdomen, and pelvis, the panel recommends pretreatment CT or MRI imaging to obtain a baseline evaluation. The panel suggests follow-up imaging every 6 to 16 weeks as per physician discretion and patient clinical status, adjusting the imaging intervals according to the rate of disease change and sites of active disease. The panel also suggests considering CT or MRI of the brain at baseline and as clinically indicated. Annual surveillance brain MRI or CT scans can be performed according to physician discretion. Other imaging tests, such as MRI of the spine and bone scan, can be performed as clinically indicated.

Conclusions

The NCCN Guidelines are in continuous evolution. They are updated annually, and sometimes more often if new high-quality clinical data become available in the interim. The recommendations in the NCCN Guidelines, with few exceptions, are based on evidence from clinical trials. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. The physician and the patient have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. When possible, consistent with NCCN philosophy, the panel strongly encourages patient/physician participation in prospective clinical trials. To view the full and most recent version of the NCCN Guidelines for Kidney Cancer, visit NCCN.org

References


Instructions for Completion

To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/60898; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet.

Posttest Questions

1. In the recently updated NCCN Guidelines for Kidney Cancer (Version 3.2015), which of the following agents is a new first-line treatment option for patients with predominantly clear cell carcinoma?
   a. Pazopanib
   b. Axitinib
   c. Everolimus
2. For patients with predominantly clear cell carcinoma, in which of the following instances does pazopanib have a lower level of evidence (phase II data) supporting its use?
   a. As first-line therapy
   b. As subsequent therapy after initial therapy with a tyrosine kinase inhibitor
   c. As subsequent therapy after initial therapy with a cytokine
3. True or False: Data show that relapses may occur after 5 years of surgical removal of primary RCC in a subset of patients.